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Abstract
Peptidergic signaling regulates cardiac contractility; thus, identifying molecular switches, li-
gand-receptor contacts, and antagonists aids in exploring the underlying mechanisms to in-
fluence health. Myosuppressin (MS), a decapeptide, diminishes cardiac contractility and
gut motility. Myosuppressin binds to G protein-coupled receptor (GPCR) proteins. Two Dro-
sophila melanogastermyosuppressin receptors (DrmMS-Rs) exist; however, no mecha-
nism underlying MS-R activation is reported. We predicted DrmMS-Rs contained molecular
switches that resembled those of Rhodopsin. Additionally, we believed DrmMS-DrmMS-R1
and DrmMS-DrmMS-R2 interactions would reflect our structure-activity relationship (SAR)
data. We hypothesized agonist- and antagonist-receptor contacts would differ from one an-
other depending on activity. Lastly, we expected our study to apply to other species; we test-
ed this hypothesis in Rhodnius prolixus, the Chagas disease vector. Searching DrmMS-Rs
for molecular switches led to the discovery of a unique ionic lock and a novel 3–6 lock, as
well as transmission and tyrosine toggle switches. The DrmMS-DrmMS-R1 and DrmMS-
DrmMS-R2 contacts suggested tissue-specific signaling existed, which was in line with our
SAR data. We identified R. prolixus (Rhp)MS-R and discovered it, too, contained the unique
myosuppressin ionic lock and novel 3–6 lock found in DrmMS-Rs as well as transmission
and tyrosine toggle switches. Further, these motifs were present in red flour beetle, common
water flea, honey bee, domestic silkworm, and termite MS-Rs. RhpMS and DrmMS de-
creased R. prolixus cardiac contractility dose dependently with EC50 values of 140 nM and
50 nM. Based on ligand-receptor contacts, we designed RhpMS analogs believed to be an
active core and antagonist; testing on heart confirmed these predictions. The active core
docking mimicked RhpMS, however, the antagonist did not. Together, these data were
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consistent with the unique ionic lock, novel 3–6 lock, transmission switch, and tyrosine tog-
gle switch being involved in mechanisms underlying TM movement and MS-R activation,
and the ability of MS agonists and antagonists to influence physiology.
Introduction
Peptidergic signaling plays numerous critical roles in transmitting and regulating physiological
processes. Therefore, delineating the mechanisms that underlie these events is a powerful ap-
proach to identifying target molecules to influence health. An important first step in signaling
is when a ligand binds to a G protein-coupled receptor protein (GPCR). Ligand-receptor bind-
ing disrupts molecular switches which cause TMmovement and ultimately results in receptor
activation reviewed in [1].
Myosuppressin dramatically decreases cardiac contractility and gut motility [2, 3]. First iso-
lated as a cockroach brain peptide that affects spontaneous contractions of the gut, myosup-
pressin was subsequently found to be distributed throughout the invertebrates. The
conservation of its structure and activities, and its widespread distribution are consistent with
myosuppressin playing an important role in physiology.
Myosuppressins are members of a family of peptides with an identical C-terminal RF-NH2,
however, the N-terminal extension is unique and differs in length and sequence [4]. The identi-
cal C terminus and variant N terminus are both important in binding and activating signaling
pathways [5, 6]. FMRF-NH2, the first RF-NH2-containing peptide isolated, was identified from
a neural extract applied to a clam heart preparation [7]. This superfamily of peptides is grouped
based on XRF-NH2, where myosuppressins often contain X = L. Myosuppressins are typically
represented by X1DVX2HX3FLRF-NH2, where X1 = pQ, P, T, A; X2 = D, G, V; X3 = V, S [8].
Drosophila melanogastermyosuppressin (DrmMS; TDVDHVFLRF-NH2) is representative
of its peptide family [9]. DrmMS is pleotropic decreasing the frequency of both cardiac con-
tractility and gut motility. The DrmMS structure-activity relationship (SAR) for its effect on
cardiac contractility and gut motility is reported; the data are consistent with DrmMS having
distinct signaling pathways in heart and gut [8]. In addition, DrmMS binds to two putative
GPCR proteins, DrmMS-R1 and DrmMS-R2 [10]. Apart from these facts, little is known about
MS signaling. No mechanism which underlies MS receptor activation, a crucial step in signal
transduction, is described in literature. And, the design and characterization of MS antagonists
in a disease vector are molecularly and physiologically limited in scope in the literature.
The kissing bug, Rhodnius prolixus, is a vector of the Chagas disease, an important health
problem [11]. RhpMS, pQDIDHVFMRF-NH2, contains two substitutions compared to the MS
consensus structure; V3! I3 and L8!M8 [12]. The physicochemical characteristics of myo-
suppressins are conserved with the residue replacements [12, 13]; RhpMS affects R. prolixus
heart rate [14]. The unique MS provides an opportunity to further explore a pathway that affects
a crucial physiological function in a disease vector. Previously, little was known about RhpMS
signaling; its receptor sequence and structure was unidentified and its SAR uncharacterized.
This study tested our prediction that MS signaling would mimic mechanisms involved in Rho-
dopsin activation. We searched for molecular switch motifs across DrmMS-Rs and discovered the
unique ionic lock and novel 3–6 lock, in addition to the transmission and tyrosine toggle switches.
We also tested our belief that DrmMS-DrmMS-R1 and DrmMS-DmrMS-R2 interactions would
reflect our SAR data, which it did. When DrmMS and its N-terminal truncation and alanyl-substi-
tuted analogs were docked to the DrmMS-Rs, the ligand contacts were distinct between receptors
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consistent with our SAR data. DrmMS interactions with DrmMS-R2 mirrored the cardiac contrac-
tility SAR data and DrmMS-DrmMS-R1 interactions reflected the gut motility data. Additionally,
we hypothesized agonist- and antagonist-receptor contacts would differ from one another reflect-
ing activity and inactivity. The docking data confirmed this prediction; agonists mirrored DrmMS
interactions, yet an inactive analog failed to mimic parent peptide contacts.
Lastly, we expected our study to apply to other species; we tested this hypothesis in R. prolixus.
We investigated RhpMS-R structure, binding pockets, ligand contacts, and SAR.We identified
the R. prolixus receptor and found it shared substantial sequence identity to DrmMS-R1 and
DrmMS-R2, 56% and 51%, respectively. The predicted protein was modeled to find the receptor
contained typical GPCR features. RhpMS-R contained the unique myosuppressin ionic lock and
novel 3–6 lock, and the transmission and tyrosine toggle switches, which, upon ligand binding,
promoted TMmovement and receptor activation. We obtained further support for the role of
the unique and novel locks by identifying and modeling the red flour beetle, common water flea,
honey bee, domestic hornworm, and termite MS-Rs; their structures, too, contained the myosup-
pressin motifs, which were likely involved in TMmovement and receptor activation.
Due to the conservation of physicochemistry of the amino acids, which differed between the
peptides and the high receptor sequence identity, we predicted RhpMS and DrmMS would be alike
in activity and ligand contacts. RhpMS and DrmMS decreased R. prolixus cardiac contractility dose
dependently with EC50 values of 140 nM and 50 nM, respectively. Based on ligand-receptor con-
tacts, analogs were predicted to be an RhpMS agonist or inactive and act as an antagonist. [5–10]
RhpMSmimicked the full-length peptide; [6–10]RhpMS applied to R. prolixus heart was inactive
and blocked the effect of the parent peptide. Together, data from these studies confirmed tissue
specificity inMS signaling, and supported the roles of a unique and a novel lock in MS-R activation.
Materials and Methods
Ethics statement
This research utilized an invertebrate, R. prolixus, reared according to a protocol in complete
agreement with the recommendation established the by Directive 2010/63/EU pf the European
Parliament and the Resolution 1047/2005 Annex II of the National Council of Scientific and
Technical Researches (COINCET; Buenos Aires, Argentina) related to the protection of ani-
mals used for scientific purposes.
Animals
R. prolixus were maintained at 28°C under high humidity in a cycle of 12h:12h (L:D). The in-
sects used were 5th instar 2–3 weeks post-ecdysis fed on chicken blood.
Chemicals
All peptides were synthesized on a 433A Applied Biosystems peptide synthesizer using stan-
dard Fmoc procedures and purified by reversed-phase high performance liquid chromatogra-
phy. Each synthesis was obtained with95% purity and identified by matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry. Peptides were diluted in series with
physiological saline to obtain the working solutions.
Bioassays
Fifth instar R. prolixus were placed ventral surface down on a dish with paraffin wax and dis-
sected under physiological saline. Segments four to seven from the dorsal abdominal cuticle
were removed using minuten pins leaving the dorsal vessel exposed. The semi-intact
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preparation was equilibrated in 20 μl saline for 20 minutes at room temperature (25° ± 2°C), re-
placing the fluid with fresh saline every five minutes. Heart rate was measured under saline
after the final bath, counting the number of contractions in one minute. This counting was rep-
licated three times for each preparation, and the results of the three countings were averaged.
After this, the saline was removed and replaced with an equal volume of solution containing a
peptide. The heart rate was measured and expressed as % of the control (saline). Ten animals
were analyzed for control and for each experiment. The investigator who performed the bioas-
say was unaware of the peptide structures being tested.
Data analysis
Dose response curves were generated and the effective concentrations at half-maximal re-
sponse (EC50) values were calculated using a non-linear regression with GraphPad Prism ver-
sion 6.03. Activities of RhpMS, DrmMS, and analogs were compared to saline, set at 100%,
using Single Factor ANOVA to calculate p values; significance was set at p 0.05.
Receptor identification and modeling
RhpMS-R was identified in the R. prolixus genome database (www.vectorbase.org) using
DrmMS-Rs as queries. The NIH database was searched with DrmMS-R1 and DrmMS-R2 to
find the primary sequences of MS-Rs in termite, Zootermopis nevadensis, (Accession #
KDR23127.1), the red flour beetle, Tribolium castaneum, (Accession # EFA01374.1), com-
mon water flea, Daphnia pulex, (Accession # EFx86411.1), domestic silkworm, Bombyx mori,
(Accession # NP_001036929.1), and honey bee, Apis mellifera (Accession #s ACI90287.1;
ACI90288.1). Alignment with DrmMS-Rs tested the likelihood a sequence represented a
MS-R. The latter was also confirmed by phylogenetic analysis (Ons et al. manuscript
submitted).
Receptor structures were modeled by I-TASSER using multiple threading alignments
zhanglab.ccmb.med.umich.edu/I-TASSER/ [15] as described [5, 6]. The top model was submit-
ted to ModRefiner zhanglab.ccmb.med.umich.edu/ModRefiner/ [16] after which the receptor
structures were viewed in PyMOL [The PyMOLMolecular Graphics System version 1.7.0.3,
Schrödinger, LLC]. The binding pocket location was considered during ligand docking bound-
ary selection. Receptor model files were modified to include polar hydrogens and converted to
the file type used for the docking procedure with AutoDockTools v 4.2 [17].
Ligand docking and analysis
Ligand models were built in PyMOL and prepared for docking in AutoDockTools as previously
described [5]. PyMOL and the molecular docking software AutoDock Vina [18] were used to
dock ligands [5]. A similar method was employed to investigate peptide docking [19]. Physico-
chemical properties, type and proximity of ligand-receptor contacts, and pose overlap were
used to evaluate the one group most likely to represent docking. Poses with strong contacts
formed multiple favorable ligand-receptor interactions within reference distances [5, 20]. All
poses were independently analyzed by two researchers.
Results
DrmMS-Rs: molecular switches, binding pockets, and ligand contacts
To begin our studies, we predicted DrmMS-Rs contained molecular switches that resembled
those of Rhodopsin. DrmMS-Rs are classified as members of the Rhodopsin family A receptors
[6]; as such, we expected them to contain an ionic lock, 3–7 lock, transmission switch, and
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tyrosine toggle switch [1]. No MS-R molecular switch was previously reported in the literature.
The DrmMS-R structures contained structural motifs reminiscent of those present in Rhodop-
sin. The ionic lock switch was represented by the WRY motif on TM3 [Fig. 1]. It was present in
the DrmMS-Rs in the same location as ERY in Rhodopsin (PDB ID: 1F88) [20]. The WRY
motif of DrmMS-R interacted with multiple T residues on TM6. Even so, DrmMS-R lost an
electrostatic interaction between TM3 and TM6 due to the absence of a negatively-charged res-
idue on TM6 within the range of a salt bridge. Also, because WRY did not contain E it could
not form an intra-motif interaction with R130/125 (notation used to indicate R130 in DrmMS-
R1 and R125 in DrmMS-R2).
A novel 3–6 lock was also discovered. It sat between TM3 and TM6 limiting the movement
of TM6 and maintaining the inactive state of the receptor. The 3–6 lock mirrored the 3–7 lock
of Rhodopsin. When the lock was disrupted, TM6 likely moved and the receptor was activated
[21]. TM7 in DrmMS-Rs did not contain a P residue, thus, it was more rigid than Rhodopsin
and less likely to disrupt the resting state of the receptor. This was one reason stabilization of
transmembrane 7 was unnecessary. TM6 was stabilized by the 3–6 lock with a salt bridge inter-
action between H116/114 on TM3 and E265/369 on TM6.
The DrmMS-Rs contained the TEFP transmission switch on TM6 in the same location as
the CWLP motif in Rhodopsin [22]. Further, F361/365 located one helix turn away from E365/
369 on TM6, H116/114 on TM3, and P284/292 located nearby on TM5 in DrmMS-Rs, were in
the same position as in Rhodopsin. A notable difference was E365/369 replaced W265, which
was stabilized through ionic interactions with H116/114 on TM3, K281/289 on TM5, and
Fig 1. DrmMS-Rsmolecular switches.DrmMS-Rs contained a unique ionic lock and novel 3–6 lock that stabilized the inactive state of the receptor.
Residues involved in the ionic lock (top left), 3–6 lock (top right), transmission switch (bottom left), and tyrosine toggle switch (bottom right) are shown for
DrmMS-R1 (blue) and DrmMS-R2 (gold). The receptors are shown as ribbons with TM1–7 labeled.
doi:10.1371/journal.pone.0120492.g001
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Q368/372 on TM7 in the DrmMS-Rs. Lastly, in the DrmMS-Rs, NFILY was similar to the Rho-
dopsin tyrosine toggle switch motif, NPVIY [23]. The loss of P on DrmMS-R TM7 suggested
the helix would be less likely to move. TM7 movement in Rhodopsin positions Y306 to extend
a hydrogen bond network from the binding pocket to the intracellular side of the receptor. A
loss of DrmMS-R TM7 movement suggested Y in the toggle switch may be distanced from the
hydrogen bond network. Further, in the DrmMS-Rs, S292/300 replaced Y223 on Rhodopsin
TM5, which also participated in this network. Due to the distance apart, S292/300 and the
ionic lock did not interact, although water-mediated bonds might exist. Either configuration
would result in a less extensive hydrogen bond network than observed for Rhodopsin. Togeth-
er, the presence of DrmMS-R molecular switches resembled those present in Rhodopsin, with
predictably similar roles in receptor activation.
DrmMS-Rs were compared to additional Rhodopsin-like receptors to determine the
uniqueness of the ionic and 3–6 locks. The inactive states of the A2A adenosine (A2AR; PDB ID:
3EML), β2-adrenergic (β2AR; PDB ID: 3NY9), chemokine CXCR4 (CXCR4; PDB ID: 3ODU),
dopamine D3 (D3R; PDB ID: 3PBL), and histamine H1 (H1R; PDB ID: 3RZE) receptors re-
viewed in Trzaskowski et al. were used in this comparison [24, 25, 26, 27, 28]. The ionic lock in
DrmMS-Rs was similar to that in H1R, which formed a hydrogen bond between R125 and
Q416; there was lack of evidence for an ionic lock in A2AR, β2AR, and CKCR4, and the lock in
D3R resembled that of Rhodopsin. DrmMS-Rs were the only receptors to show the presence of
a 3–6 lock, all other receptors, with the exception of A2AR, contained a 3–7 lock. The transmis-
sion and tyrosine toggle switches between MS-Rs and additional Rhodopsin-like receptors are
highly similar.
Next, we believed DrmMS-R1 and DrmMS-R2 interactions would reflect our SAR data [8].
This hypothesis required identifying and characterizing the DrmMS-R1 and DrmMS-R2 bind-
ing pockets. The DrmMS-R binding pockets (Fig. 2, Fig. 3) were similar to each other in shape,
size, and physicochemical characteristics, but each was characterized by some unique features
(Table 1, Table 2). In DrmMS-R2, W165 was between TM4 and TM5 excluding Y284 on TM5;
Fig 2. DrmMS-R1model. The exposed atoms at the surface of the ligand-binding pocket are highlighted as
carbon (gray), oxygen (red), and nitrogen (blue). The pocket contained a polar region between TM6 and TM7,
and separate hydrophobic and aromatic regions near TM1 and TM5. DrmMS-R1 was undefined between
TM1 and TM7, and TM4 and TM5.
doi:10.1371/journal.pone.0120492.g002
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due to its size, S167 in DrmMS-R1 did not mimic W165. Q269 in DrmMS-R1 and R277 in
DrmMS-R2 differed in charge. In DrmMS-R1, K25 rotated out, yet, in DrmMS-R2, K23 was
exposed resulting in a charge on TM1. In DrmMS-R1, H116 rotated toward K281 on TM6 to
block access to a hydrophobic region to the center of the pocket in DrmMS-R1. Contrary, in
DrmMS-R2, H114 rotated toward TM7 increasing access to this region. Y276 on TM5 in
DrmMS-R1 increased the hydrophobic character, yet, the rotation of Y284 in DrmMS-R2
moved F281 further into the pocket. Together with the H114 rotation, the absence of Y284 in
the pocket led to accessibility of the hydrophobic region around TM4. Also, ECL2 in DrmMS-
R2 was structured with helices and beta sheets, but, in DrmMS-R1, it was predicted to have no
secondary structure, making it flexible enough to be modeled between TM1 and TM7. The
unique binding pockets were consistent with tissue-specific signaling as inferred by our
SAR data.
[6–10]DrmMS was the heart rate active core, yet [4–10]DrmMS was the gut motility active
core. The alanine scans performed in heart and gut showed the residues crucial to DrmMS ac-
tivity and binding are different between the two tissues; F7 and L8 were essential in gut, and F7
Fig 3. DrmMS-R2model. The receptor backbone, binding pocket, with the exposed atoms are highlighted,
and TMs are shown; refer to Fig. 2 for notation. The deepest portion of the pocket was in the region near TM5.
DrmMS-R2 contained a highly polar region between TM6 and TM7 and two hydrophobic and aromatic
regions near TM1 and TM5.
doi:10.1371/journal.pone.0120492.g003
Table 1. Residue identity differences between DrmMS-Rs.
DrmMS-R1 DrmMS-R2
TM1 V31 F29
TM3 I110 V108
A112 P110
TM4 S167 W165
TM5 Q269 R277
TM6 A376 V380
TM7 R389 K393
doi:10.1371/journal.pone.0120492.t001
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and F10 in heart. We believed DrmMS-DrmMS-R1 and DrmMS-DrmMS-R2 interactions
would reflect our SAR data. N-terminal truncated and alanyl-substituted analogs (Table 3)
were docked to the receptors; additional data are available in Supporting Information. In
DrmMS docked to DrmMS-R1 (Fig. 4, Table 4), F7 made multiple, strong hydrophobic and ar-
omatic contacts, which L8 extended by interacting with hydrophobic residues on TM1, TM2
and TM7. H5, V6, and F10 formed additional hydrophobic contacts between TM4, TM5, and
TM6; H5 made extensive interactions within this region. The N-terminal residues formed
weaker hydrophobic and polar interactions to TM2 and TM3. In DrmMS-R2 (Fig. 5, Table 5),
Table 2. Rotameric differences between DrmMS-Rs.
DrmMS-R1 DrmMS-R2
TM1 K25 K23
S32 S30
TM2 V73 V71
M74 M72
Y77 Y75
TM3 F104 F102
I105 I103
H108 H106
Q113 Q111
L115 L113
H116 H114
S119 S117
TM5 N270 N278
T272 T280
F273 F281
Y276 Y284
K281 K289
TM6 E365 E369
Q368 Q372
M371 M375
N375 N379
TM7 S391 S395
I396 I400
L399 L401
doi:10.1371/journal.pone.0120492.t002
Table 3. DrmMS and analogs: structures and activities.
Peptide Structure Gut Heart
DrmMS TDVDHVFLRF-NH2 agonist agonist
[A8] DrmMS TDVDHVFARF-NH2 inactive agonist
[4–10]DrmMS DHVFLRF-NH2 active core agonist
[5–10]DrmMS HVFLRF-NH2 antagonist agonist
[6–10]DrmMS VFLRF-NH2 inactive active core
[7–10]DrmMS FLRF-NH2 inactive inactive
Y-Bpa2DrmMS Y-T(Bpa)VDHVFLRF-NH2 agonist agonist
Y-Bpa4DrmMS Y-TDV(Bpa)HVFLRF-NH2 agonist antagonist
doi:10.1371/journal.pone.0120492.t003
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F7 formed contacts between TM1 and TM2; the position of F10 on TM7 allowed for hydropho-
bic and aromatic interactions with ECL3. D2 and R9 interacted and formed an ionic network
near TM6. D4 made extensive intramolecular interactions with the backbone to stabilize the
peptide. The N terminus spanned the pocket to make hydrophobic and polar interactions with
TM3, TM4, and TM5. The residues which formed strong interactions differed between the
DrmMS-Rs, in particular, L8, F7, and F10 showed receptor-specific ligand binding in line with
our tissue-specific SAR data.
In [4–10]DrmMS, active in heart and the active core in gut, docked to DrmMS-R1 (Fig. 6,
Table 6), F7 initiated a hydrophobic network that was extended by L8 to the TM1, TM2, and
TM7 interface. V6 and F10 contributed to this network by making contacts near TM2 and TM3,
respectively. In DrmMS-R2, the analog mimicked DrmMS, though the contacts were not made by
the same residues (Fig. 7, Table 7). F10 spanned the pocket to pi-stack to TM5. The C-terminal
amide docked between TM6 and TM7 leading R9 to form hydrogen bonds with TM3, D4, and
H5, which created a large hydrogen bond network extending to the bottom of the pocket. V6 and
F7 maintained DrmMS-like contacts and interacted with each other, creating a small hydrophobic
network between TM1 and TM2. The absence of three N-terminal residues did not change the
backbone conformation or contacts relative to DrmMS. Thus, the contact sites between [4–10]
DrmMS and the DrmMS-Rs were consistent with the analog being active in heart and gut.
In [6–10]DrmMS, the active core in heart, but inactive in gut, docked to DrmMS-R1 (Fig. 8,
Table 8), F7 maintained multiple, strong hydrophobic and aromatic contacts, extending deeper
into the pocket compared to DrmMS. L8 was directed towards TM1 and TM2 and failed to
make contacts with F7. V6 made hydrophobic contacts. R9 and F10 filled the pocket yet failed
to retain many DrmMS-like contacts. [6–10]DrmMS docked to DrmMS-R2 was similar to
DrmMS (Fig. 9, Table 9). F10 interacted with hydrophobic and aromatic residues on TM1 and
TM2. V6, F7, and L8 made hydrophobic contacts to TM3, TM4, and TM5, pi-stacked with
TM5, and retained N-terminal contacts. F7 and F10 maintained strong interactions within sep-
arate networks in the pocket, much like DrmMS. The similar contacts suggested a role for
DrmMS-R2 signaling in heart. In [7–10]DrmMS, inactive in heart, docked to DrmMS-R2
(Fig. 10, Table 10) the analog location was similar to [6–10]DrmMS and F7 contacts were
Fig 4. DrmMS docked to DrmMS-R1. The DrmMS ligand is shown docked to DmsMS-R1 as T1(salmon),
D2 (olive), V3 (wheat), D4 (cyan), H5 (yellow), V6 (hot pink), F7 (orange), L8 (light blue), R9 (red), and F10
(blue). F7 and L8 formed a large hydrophobic network extending from the center of the pocket to TM1.
doi:10.1371/journal.pone.0120492.g004
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Table 4. DrmMS contact sites on DrmMS-R1a.
T Side chain Y77 2.9 Å
T81 4.7 Å
Y85 4.5 Å
H108 1.8 Å
Backbone D84 2.8 Å
D2 3.6 Å
V3 (NH) 3.8 Å
D Side chain T1 3.6 Å
Backbone S109 4.1 Å
V Side chain A112 4.9 Å
F7 4.4 Å
Backbone T1 (CO) 3.8 Å
D Side chain Q113 2.7 Å
S167 3.8 Å
H5 4.1 Å, (NH) 4.0 Å
Backbone Q113 2.2 Å
H5 3.7 Å
H Side chain Q113 3.6 Å
S167 5.1 Å
T272 4.1 Å
F273 5.0 Å
Y276 2.4 Å
Backbone Q113 2.7 Å
D4 4.0 Å
F7 (NH) 3.3 Å
V Side chain F273 5.0 Å
Y276 4.5 Å
M371 4.7 Å
F10 3.9 Å
Backbone Q368 2.5 Å
F Side chain V73 3.5 Å
Y77 3.1 Å
A112 2.8 Å
H116 4.2 Å
L399 3.9 Å
L8 3.7 Å
Backbone Q368 3.8 Å
H5 (CO) 3.3 Å
L Side chain Y77 3.6 Å
I396 4.9 Å
L399 3.8 Å
F7 3.7 Å
Backbone F10 (NH) 3.3 Å
R Side chain Y24 3.7 Å
D392 2.8 Å
Backbone —
F Side chain F273 3.1 Å
M371 2.3 Å
G372 3.8 Å
V6 3.9 Å
Backbone D392 2.1 Å
D395 2.1 Å
L8 (CO) 3.3 Å
NH2 S391 3.4 Å
D392 2.4 Å
D395 2.8 Å
aResidues numbered 1–10 are in DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone group was contacted. In the case in which a
residue was contacted twice by the backbone of the same ligand residue, O and H are used to distinguish the contacts.
doi:10.1371/journal.pone.0120492.t004
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identical. However, the loss of V6 changed the backbone conformation and altered the L8 and
R9 side chain orientations and contacts. The largest difference was the rotation of F4, it con-
tacted hydrophobic residues between TM2 and TM3, losing contacts to TM1 and TM2. [7–10]
DrmMS resulted in weaker ligand-receptor contacts compared to [6–10]DrmMS, consistent
with inactivity versus activity of these analogs in heart.
In [A8]DrmMS, inactive in gut, but active in heart, docked to DrmMS-R1, the C terminus
was shifted relative to DrmMS (Fig. 11, Table 11). F7 formed multiple strong hydrophobic and
aromatic contacts, and V6 contributed to a hydrophobic network. A8 of the analog was similar-
ly positioned to L8, but its smaller side chain did not retain the contacts, thus, the hydrophobic
network between L8, F7, the pocket bottom and the region around TM1, TM2, and TM7 were
weakened. In DrmMS-R2 (Fig. 12, Table 12), [A8]DrmMS and DrmMS differed in D4 side
chain orientation; D4 was rotated toward R9 increasing the ionic network in comparison to
DrmMS. [A8]DrmMS contacts were consistent with the peptide signaling through DrmMS-R2
in heart.
Docking agonists and antagonists identified contacts required to bind a ligand and to acti-
vate a receptor. In DrmMS and [4–10]DrmMS docked to DrmMS-R1, H116 in the MS-R 3–6
lock may rotate toward TM7 to strengthen the network formed by F7 and L8 thus weakening
the salt bridge between TM3 and TM6 and disrupting the DrmMS-R1 3–6 lock allowing recep-
tor activation. However, in [6–10]DrmMS, F7 docked deeper in the pocket and did not allow
H116 to rotate toward TM7 or disrupt the 3–6 lock, preventing TM6 movement and receptor
activation. The position of F7 in [A8]DrmMS allowed the rotation of H116 toward TM7, yet
the F7 and L8 network was greatly weakened, and the hydrophobic contacts extending up to
TM7 were absent, consistent with the lack of receptor activation.
When docked to DrmMS-R2, DrmMS, [4–10]DrmMS, and [A8]DrmMS contacted H114,
K289, and Q372, receptor residues comprising and interacting with the 3–6 lock. H114 rotated
to the extracellular side of the receptor to make strong contacts with the ligand, distancing it
Fig 5. DrmMS docked to DrmMS-R2. The DrmMS ligand is shown docked to DrmMS-R2; see Fig. 4 for
notation of the amino acids. Residues in the C-terminal region, particularly F7 and F10, made strong
hydrophobic and aromatic contacts. D2 and R9 formed an ionic network near TM6 and the N terminus filled
the remainder of the binding pocket.
doi:10.1371/journal.pone.0120492.g005
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Table 5. DrmMS contact sites on DrmMS-R2a.
T Side chain Q111 3.5 Å
T115 3.3 Å
V161 3.3 Å
V162 4.6 Å
W165 4.3 Å, OH 2.7 Å
D2 (NH) 2.9 Å, (CO) 3.7 Å
Backbone S285 4.1 Å
K289 3.8 Å
D Side chain K289 2.8 Å
Q372 4.1 Å
V3 (NH) 2.4 Å
R9 2.9 Å
Backbone Q111 3.6 Å
T1 H 2.9 Å, O 3.7 Å
H5 3.0 Å
V Side chain F281 3.7 Å
G376 3.9 Å
Backbone H5 3.5 Å
D2 2.4 Å
D Side chain H5 (NH) 3.0 Å
V6 (NH) 2.0 Å
F7 (NH) 3.5 Å
L8 (NH) 4.0 Å
Backbone R9 2.2 Å
H Side chain V3 (CO) 3.2 Å
H106 4.9 Å
P110 3.6 Å
D2 (CO) 3.0 Å
H114 4.5 Å
Backbone Y83 3.0 Å
D4 3.0 Å
V Side chain Y78 4.3 Å
T79 4.3 Å
H106 3.5 Å
Backbone Y83 3.6 Å
D4 2.0 Å
F Side chain Y22 4.7 Å
K23 4.0 Å
H26 4.7 Å
Y83 3.9 Å
L8 4.4 Å
Backbone S395 2.7 Å
D4 3.5 Å
L Side chain L392 3.6 Å
F7 4.4 Å
Backbone D4 4.0 Å
R Side chain Q372 2.6 Å
D399 3.7 Å
D2 3.6 Å
D4 (CO) 2.2 Å
Backbone N379 3.4 Å
Y391 2.7 Å
S395 3.8 Å
NH2 2.4 Å
F Side chain F386 3.7 Å
Y391 3.5 Å
Backbone —
NH2 R9 (CO) 2.4 Å
aResidues numbered 1–10 are in DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone group was contacted. In the case in which a
residue was contacted twice by the backbone of the same ligand residue, O and H are used to distinguish the contacts.
doi:10.1371/journal.pone.0120492.t005
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from E369 and weakening the 3–6 lock. [6–10]DrmMS lacked polar interactions to the 3–6
lock and surrounding residues. However, L8 interacted with H114 inducing it to rotate and
form stronger contacts, weakening the 3–6 lock. Further, [6–10]DrmMS retained F7 contacts
of DrmMS to TM1 and TM2. Finally, [7–10]DrmMS lacked interactions with H114, K289, and
Q372 and the hydrophobic residues on TM1 and TM2. Agonists and antagonist interactions
with DrmMS-R2 were consistent with the SAR data in heart. Docking of agonists versus antag-
onist indicated that contacts to H114, K289, and Q372 and residues on TM1 and TM2 were
crucial for receptor activation.
RhpMS: receptor, molecular switches, ligand contacts, and SAR
We identified RhpMS-R in the R. prolixus genome database (www.vectorbase.org) using
DrmMS-Rs as queries; it was contained in a single exon gene, Supercontig GL56309. RhpMS-R
shared 56% sequence identity with DrmMS-R1 and 52% with DrmMS-R2. The hydrophobic
and aromatic residues on TM2 and TM3 created a region analogous to that seen in the
DrmMS-Rs (Fig. 13). K218 on TM5 was rotated out compared to DrmMS-R1 and DrmMS-R2.
F210 and Y213 on TM5 were available to make strong aromatic interactions. Finally, residues
on TM6 and TM7, including E281, Q284, D308, and D311, created a polar region that included
a nearby residue, H114.
RhpMS-R was searched to identify molecular switches; it contained a unique ionic lock rep-
resented by a WRY motif on TM3 (Fig. 14). R128 of RhpMS-R formed a hydrogen-bond net-
work with multiple T residues on TM6. The ionic lock did not form an electrostatic interaction
due to the lack of a negatively charged residue on TM6 or within the WRY motif. The novel
3–6 lock was also present in RhpMS-R. Similar to DrmMS-Rs, RhpMS-R did not contain a P
residue on TM7, indicating that stabilization of TM7 through a 3–7 lock would not be neces-
sary. Rather, the 3–6 lock of RhpMS-R involved the formation of a salt bridge between H114
on TM3 and E281 on TM6, limiting the movement of TM6 and stabilizing the inactive state of
Fig 6. [4–10]DrmMS docked to DrmMS-R1. [4–10]DrmMS retained many of the DrmMS contact sites with
DrmMS-R1 thus mimicking the parent peptide, consistent with SAR data that indicate the analog is active in
heart and gut. See Fig. 4 for notation of the ligand amino acids.
doi:10.1371/journal.pone.0120492.g006
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Table 6. [4–10]DrmMS contact sites on DrmMS-R1a.
D Side chain Q113 3.2 Å
Y276 3.6 Å
Backbone H5 3.3 Å
H Side chain F273 3.5 Å
M371 3.6 Å
D2 (NH) 3.3 Å
Backbone K281 3.5 Å
Q368 3.1 Å
V Side chain A112 4.2 Å
H116 3.7 Å
Y276 4.9 Å
F7 3.8 Å
F10 3.7 Å
Backbone Q368 3.1 Å
F Side chain V73 3.5 Å
Y77 3.7 Å
A112 3.7 Å
L115 4.8 Å
H116 4.0 Å
L399 3.7 Å
V6 3.8 Å
Backbone Q368 3.7 Å
L Side chain H28 4.1 Å
Y85 4.5 Å
I396 3.6 Å
L399 4.5 Å
Backbone —
R Side chain D84 2.3 Å
Y85 4.1 Å
H108 3.0 Å
R9 (CO) 3.2 Å
F10 (CO) 3.0 Å
NH2 3.2 Å
Backbone Y77 O 3.0 Å, H 3.5 Å
H108 3.2 Å
R9 3.2 Å
F Side chain Y77 4.5 Å
H108 4.4 Å
A112 3.8 Å
V6 3.7 Å
Backbone R9 3.0 Å
NH2 H108 3.7 Å
R9 3.2 Å
aResidues numbered 1–10 are in DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone group was contacted. In the case in which a
residue was contacted twice by the backbone of the same ligand residue, O and H are used to distinguish the contacts.
doi:10.1371/journal.pone.0120492.t006
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the receptor. Receptor activation would involve the disruption of the 3–6 lock to allow for the
movement of TM6.
RhpMS-R contained a TEFP motif on TM6 identical to that of the DrmMS-Rs (Fig. 14).
The polar character of the RhpMS-R pocket favored the presence of E281 in comparison to
W265 in Rhodopsin. Further, E281 was stabilized through the 3–6 lock with an ionic interac-
tion to H114. The conservation of the motif and presence of F227 on TM6, H114 on TM3, and
P221 on TM5 indicated that the function of the transmission switch, inducing receptor activa-
tion through TM3-TM5-TM6 structural changes upon agonist binding [22], was maintained.
The NFMIY motif on TM7 in RhpMS-R was structurally similar to NFILY in DrmMS-Rs, its
tyrosine toggle switch. The lack of a P residue in TM7 suggested that Y325 was moved from a
hydrogen bond network to the intracellular side of the receptor upon activation. Further,
RhpMS-R contained S229 on TM5 which was unable to reach the hydrogen bond network. Ad-
ditional work to model and search B.mori (BomMS-R), A.mellifera (ApmMS-R1 and
ApmMS-R2), D. pulex (DapMS-R), T. castaneum (TrcMS-R), and Z. nevadensis (ZonMS-R)
showed a conservation of the 3–6 lock within the MS-Rs (Fig. 15).
In RhpMS docked to RhpMS-R (Fig. 16, Table 13) F7 and F10 interacted with hydrophobic
and aromatic regions, and R9 formed a salt bridge between TM6 and TM7. D4 made strong
contacts, forming salt bridge interactions and extending an ionic network initiated by R9. H5
interacted extensively with the backbone and C-terminal amide to stabilize the ligand. I3, H5,
V6, M8 and R9 contacts in RhpMS resembled those of DrmMS docked to DrmMS-R2. Howev-
er, RhpMS was slightly shifted; Y391 on TM7 that pi-stacked with DrmMS F10 was modeled as
part of ECL3 in RhpMS-R, which caused F10 to pi-stack with F210 on TM5. K23 on TM1 of
DrmMS-R2 was R25 in RhpMS-R, which altered the orientations of nearby residues and re-
sulted in F7 docking between TM2 and TM3 instead of TM1 and TM7 as in DrmMS. K218 on
TM5, analogous to K289 on DrmMS-R2 that contacted D2 in DrmMS, was outside of the
pocket in RhpMS-R and, thus, was unable to dock favorably. However, D4 was rotated and in-
teracted with R9 maintaining an ionic network to TM7 as in DrmMS. Due to its size, pQ1
Fig 7. [4–10]DrmMS docked to DrmMS-R2. [4–10]DrmMS retained many of the DrmMS contact sites with
DrmMS-R2, thus mimicking the parent peptide, consistent with SAR data that indicate the analog is active in
heart and gut. See Fig. 4 for notation of the ligand amino acids.
doi:10.1371/journal.pone.0120492.g007
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Table 7. [4–10]DrmMS contact sites on DrmMS-R2a.
D Side chain H106 3.1 Å
H5 (NH) 2.8 Å
V6 (NH) 2.3 Å
Backbone F7 (NH) 4.1 Å
R9 2.6 Å, (NH) 3.8 Å
F10 (NH) 3.3 Å
H Side chain Y75 3.9 Å
H106 4.0 Å
P110 3.7 Å
H114 3.6 Å
Q372 3.1 Å
R9 3.5 Å
F10 (CO) 2.0 Å
Backbone Y75 2.7 Å
H106 2.3 Å
D4 2.8 Å
V Side chain T79 3.6 Å
Y83 3.8 Å
H106 4.9 Å
F7 3.7 Å
Backbone Y83 3.3 Å
D4 2.3 Å
F Side chain Y22 4.7 Å
K23 3.9 Å
Y83 3.6 Å
V6 3.7 Å
Backbone S395 3.0 Å
D4 (CO) 4.1 Å
L Side chain Y391 3.7 Å
L392 3.6 Å
Backbone —
R Side chain S107 3.7 Å
Q111 2.9 Å
D4 (CO) 2.6 Å
H5 3.5 Å
Backbone N379 4.3 Å
D399 3.9 Å
D4 (CO) 3.8 Å
F Side chain W165 3.6 Å
F281 3.6 Å
G376 5.0 Å
Backbone D4 (CO) 3.3 Å
H5 2.0 Å
NH2 N379 3.2 Å
aResidues numbered 1–10 are in DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone
group was contacted. In the case in which a residue was contacted twice by the backbone of the same
ligand residue, O and H are used to distinguish the contacts.
doi:10.1371/journal.pone.0120492.t007
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could not dock as deeply between TM3, TM4, and TM5, as T1 did in DrmMS, thus, it docked
upwards between TM4 and TM5.
[4–10]RhpMS (Fig. 17, Table 14) maintained most of the interactions of the parent peptide,
although the contacts were not always retained by the same ligand residues. V6 and F7, and
F10 of the truncated analog maintained the contacts of I3 and F7, respectively, in RhpMS. D4,
H5, R9 and the C-terminal amide were involved in a large hydrogen bond network between
TM3, TM4, and TM5, retaining contacts of pQ1, D2, and H5 from RhpMS. The major differ-
ences between [4–10]RhpMS and RhpMS were the lack of an ionic network between TM6 and
TM7 and contacts to the top of TM5 and TM6 in [4–10]RhpMS, interactions made by D2, R9,
and F10 in RhpMS. [5–10]RhpMS (Fig. 18, Table 15) also maintained many contacts of the
parent peptide with its N terminus similar to [4–10]RhpMS. [5–10]RhpMS H5 and the C-ter-
minal amide, and F10 retained the contacts of R9 and F7 of RhpMS. Although [5–10]RhpMS
R9 formed hydrogen bonds to TM3 and interacted extensively with the hydrophobic region
near TM5, contacts of pQ1, D2, and F10 from RhpMS were not retained. [6–10]RhpMS
(Fig. 19, Table 16) docked largely to the hydrophobic region between TM4, TM5, and TM6
with little or no contacts to TM1, TM2, TM3, or TM7. A similar hydrophobic network involv-
ing V6, F7, and M8 was not as extensive as in [5–10]RhpMS. R4 extended into the binding
pocket and formed a salt bridge interaction to TM7.
RhpMS and DrmMS dose dependently decreased R. prolixus heart rate with EC50 values of
140 nM and 50 nM, respectively (Fig. 20). The effect of N-terminally truncated analogs of
RhpMS on heart rate was measured to determine the length required to elicit RhpMS activity.
[4–10]RhpMS and [5–10]RhpMS docking was similar to that of RhpMS and thus these analogs
were predicted to mimic the response of the parent peptide. Further, docking of [6–10]RhpMS
was distinct from RhpMS and was not predicted to activate RhpMS-R. Thus, [4–10]RhpMS,
[5–10]RhpMS, and [6–10]RhpMS were tested to determine their effect on heart rate.
Fig 8. [6–10]DrmMS docked to DrmMS-R1. [6–10]RhpMS did not retain many of the DrmMS contact sites
with DrmMS-R1 thus is was unlike the parent peptide, consistent with SAR data that established it was
inactive in gut, but the active core in heart. Thus, taken together, these data indicated [6–10]DrmMS did
activate DrmMS-R1 in the gut.
doi:10.1371/journal.pone.0120492.g008
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[4–10]RhpMS decreased heart rate dose dependently, from 1 nM to 10 μM. [5–10]RhpMS
and [6–10]RhpMS were measured between 10 pM and 1 μM and [6–10]RhpMS was further
tested at 100 μM (S9 Fig.). At 1 μM, [4–10]RhpMS and [5–10]RhpMS were active with heart
contractions 49% and 50% of saline, respectively (Table 17). [6–10]RhpMS appeared to be in-
active at 1 μMwith heart rate 85% of saline (Table 17). The inactive [6–10]RhpMS was com-
peted against RhpMS to establish whether it was an antagonist. From 1 nM to 10 μM, [6–10]
RhpMS was applied with 1 μM RhpMS, a concentration which elicited a potent effect, to deter-
mine if the analog antagonized the parent peptide activity. Alone, 1 μMRhpMS decreased
Table 8. [6–10]DrmMS contact sites on DrmMS-R1a.
V Side chain H116 3.7 Å
T117 4.8 Å
Y276 4.5 Å
F10 3.5 Å
Backbone H116 3.3 Å
K281 3.7 Å
Q368 H 2.9 Å, O 3.8 Å
F Side chain V73 3.6 Å
L115 4.7 Å
H116 3.8 Å
F361 4.7 Å
L399 4.1 Å
Backbone —
L Side chain Y77 3.9 Å
T81 3.8 Å
Y85 4.8 Å
I396 5.0 Å
L399 3.7 Å
Backbone Y77 3.6 Å
F10 (NH) 4.0 Å
R Side chain Y77 3.3 Å
Q113 3.5 Å
R9 (CO) 2.9 Å
Backbone Y77 3.6 Å
R9 2.9 Å
F Side chain F273 3.6 Å
Y276 3.8 Å
G372 5.1 Å
V6 3.5 Å
Backbone Q368 4.2 Å
D392 3.6 Å
D395 2.4 Å
L8 (CO) 4.0 Å
NH2 D392 3.9 Å
D395 2.1 Å
aResidues numbered 1–10 are in DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone
group was contacted. In the case in which a residue was contacted twice by the backbone of the same
ligand residue, O and H are used to distinguish the contacts.
doi:10.1371/journal.pone.0120492.t008
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heart rate to 4% baseline and 1 μM [6–10]RhpMS was 85%; together, the result was 38% base-
line (Table 18), which indicated the analog antagonized RhpMS signaling. At lower concentra-
tions [6–10]RhpMS was less effective, and at a 10-fold higher concentration, it was a more
effective antagonist (S10 Fig.).
Activation of the receptor appeared to involve disruption of the 3–6 lock between H114 and
E281. D4 of RhpMS and the N-terminal amide of [5–10]RhpMS were positioned to form salt
bridges with H114 and E281, respectively, weakening or disrupting the 3–6 lock and allowing
TM6 to move. The ligand backbone of [4–10]RhpMS interacted minimally with H114 and
E281, possibly weakening the salt-bridge interaction. Further, [4–10]RhpMS retained contact
sites of RhpMS, suggesting the analog maintained interactions required for receptor activation.
Conversely, [6–10]RhpMS docked to the TM5 and TM6 region, lacking interactions to the 3–6
lock and forming many interactions distinct from those of RhpMS. The lack of RhpMS con-
tacts between TM2 and TM3 and the maintenance of the 3–6 lock are consistent with the inac-
tivity of the analog. However, the strength of [6–10]RhpMS ligand-receptor contacts indicate
favorable binding, consistent with it being an antagonist of RhpMS signaling. Docking data in-
dicated that interactions to the 3–6 lock and hydrophobic residues between TM2 and TM3
were required for receptor activation.
Discussion
In this paper we described molecular switches involved in TMmovement that underlies MS-R
activation; no prior publication reports these motifs and mechanisms. We found a unique
ionic lock and novel 3–6 lock held MS-Rs in an inactive state that, upon ligand binding, may
lead to TM6 movement, a crucial step for receptor activation [20, 21, 29]. A conserved TEFP
present in MS-Rs mimicked the Rhodopsin transmission switch, CWLP [22, 30]. Lastly, NF
(M/I)(I/L)Y in MS-Rs resembled the Rhodopsin tyrosine toggle switch motif, NPVIY.
Fig 9. [6–10]DrmMS docked to DrmMS-R2. [6–10]DrmMS retained many of the DrmMS contact sites with
DrmMS-R2, thus, mimicking the parent peptide consistent with SAR data that established it was inactive in
gut, but the active core in heart. Thus, taken together, these data indicated [6–10]DrmMSmay activate
DrmMS-R2 in heart.
doi:10.1371/journal.pone.0120492.g009
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The motifs were present and made contacts consistent with MS-R activation. Even so, the
motifs of the MS-Rs were unique compared to Rhodopsin, in line with the MS peptide, receptor
structures, and ligand contacts, and consistent with the DrmMS and RhpMS SAR data. The
loss of contacts and networks, and weakened interactions observed in MS-Rs compared to
Rhodopsin may indicate their transition from the inactive to active state occurs on a different
time scale or energy level.
Myosuppressins are likely to play crucial roles in physiology; however, ligand-receptor con-
tact data remained unpublished. DrmMS-R1 and DrmMS-R2 share high sequence identity and
bind the same ligand, yet, their binding pockets differed physicochemically. The unique
DrmMS-DrmMS-R1 and DrmMS-DrmMS-R2 contact data that we report and our previous
SAR data [8] were consistent with tissue-specific signaling in heart and gut. Next, we explored
MS ligand binding and receptor activation in R. prolixus. Although RhpMS-R shared high se-
quence identity with the DrmMS-Rs, its binding pocket was different in shape and size, and the
residues which projected into it. These data were in line with the unique RhpMS SAR com-
pared to DrmMS data, in particular, the differences in the RhpMS active core and antagonist
structures for R. prolixus cardiac contractility.
Table 9. [6–10]DrmMS contact sites on DrmMS-R2a.
V Side chain W165 3.8 Å
F7 3.8 Å
Backbone S107 3.0 Å
F Side chain W165 3.5 Å
F281 3.5 Å
V380 5.0 Å
V6 3.8 Å
L8 4.3 Å
Backbone S107 3.6 Å
R9 (NH) 3.7 Å
L Side chain Y75 5.1 Å
H106 4.2 Å
P110 3.9 Å
H114 4.6 Å
F7 4.3 Å
Backbone H106 2.8 Å
R Side chain Y78 3.7 Å
D82 3.2 Å
Backbone H106 4.2 Å
F7 (CO) 3.7 Å
F Side chain K23 4.4 Å
Y83 3.7 Å
Backbone Y83 3.1 Å
NH2 Y75 3.6 Å
Y83 3.1 Å
D399 3.5 Å
aResidues numbered 1–10 are in DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone
group was contacted. In the case in which a residue was contacted twice by the backbone of the same
ligand residue, O and H are used to distinguish the contacts.
doi:10.1371/journal.pone.0120492.t009
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Fig 10. [7–10]DrmMS docked to DrmMS-R2. [7–10]DrmMS did not retain many of the DrmMS contact sites
with DrmMS-R2, consistent with SAR data that indicate the analog is inactive in heart and gut. Thus, taken
together, these data indicated [7–10]DrmMS, one less N-terminal residue than [6–10]DrmMS, the active core
in heart, did not activate DrmMS-R2, in line with this receptor transducing the DrmMS-R2 signal.
doi:10.1371/journal.pone.0120492.g010
Table 10. [7–10]DrmMS ligand-receptor contact sites on DrmMS-R2a.
F Side chain W165 3.6 Å
F281 3.6 Å
V380 4.8 Å
Backbone Q111 3.7 Å
R9 (NH) 2.5 Å
L Side chain I103 4.4 Å
F10 3.7 Å
Backbone R9 3.1 Å
R Side chain Q372 3.9 Å
D399 2.9 Å
L8 (CO) 3.1 Å
Backbone Y75 3.0 Å
H106 4.0 Å
F7 (CO) 2.5 Å
F Side chain Y78 3.7 Å
I103 3.7 Å
H106 3.5 Å
L8 3.7 Å
Backbone Y75 3.0 Å
Y83 3.1 Å
D399 3.9 Å
NH2 Y83 3.1 Å
D399 2.9 Å
aResidues numbered 1–10 are in DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone
group was contacted. In the case in which a residue was contacted twice by the backbone of the same
ligand residue, O and H are used to distinguish the contacts.
doi:10.1371/journal.pone.0120492.t010
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Fig 11. [A8]DrmMS docked to DrmMS-R1. The hydrophobic network between F7 and A8 in [A8]DrmMS
was weakened in comparison to DrmMS because the branched character of the L side chain was absent.
These data indicated [A8]DrmMS did not activate DrmMS-R1. A8 is purple.
doi:10.1371/journal.pone.0120492.g011
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Table 11. [A8]DrmMS ligand-receptor contact sites on DrmMS-R1a.
T Side chain S167 3.6 Å
T272 3.8 Å
H5 2.8 Å
Backbone Q113 2.8 Å
S167 3.9 Å
D2 (CO) 4.1 Å
D Side chain N269 3.2 Å
D4 (NH) 3.8 Å
H5 2.5 Å
Backbone H5 (NH) 3.9 Å
NH2 3.5 Å
V Side chain F10 3.7 Å
Backbone V6 (NH) 4.0 Å
NH2 3.8 Å
D Side chain Y387 2.9 Å
Backbone Q368 3.9 Å
D2 3.8 Å
H Side chain F273 3.9 Å
Y276 4.6 Å
T1 2.8 Å
D2 2.5 Å
V6 3.6 Å, (NH) 3.7 Å
Backbone K281 3.2 Å
Q368 3.4 Å
D2 (CO) 3.9 Å
V Side chain H116 3.7 Å
H5 3.7 Å
F7 4.6 Å
Backbone Q368 2.9 Å
V3 (CO) 4.0 Å
H5 3.7 Å
F Side chain V73 3.6 Å
Y77 4.1 Å
A112 3.9 Å
L115 4.8 Å
H116 3.7 Å
L399 3.5 Å
V6 4.6 Å
Backbone NH2 3.9 Å
A Side chain I396 3.9 Å
L399 4.0 Å
Backbone —
R Side chain D84 2.6 Å
R9 (CO) 2.3 Å
Backbone Y77 2.8 Å
NH2 3.4 Å
F Side chain W101 3.7 Å
I105 3.7 Å
H108 3.8 Å
S109 4.4 Å
V3 3.7 Å
Backbone Y77 1.9 Å
NH2 D2 (CO) 3.5 Å
V3 (CO) 3.8 Å
R9 (CO) 3.4 Å
aResidues numbered 1–10 are in DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone group was contacted. In the case in which a
residue was contacted twice by the backbone of the same ligand residue, O and H are used to distinguish the contacts.
doi:10.1371/journal.pone.0120492.t011
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Fig 12. [A8]DrmMS docked to DrmMS-R2. [A8]DrmMS retained many of the DrmMS contact sites with
DrmMS-R2, thus, it mimicked the parent peptide consistent with the SAR data that established it was active in
heart. Thus, taken together, these data indicated [A8]DrmMS signaling involved DrmMS-R2 in heart. A8
is purple.
doi:10.1371/journal.pone.0120492.g012
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Table 12. [A8]DrmMS ligand-receptor contact sites on DrmMS-R2a.
T Side chain T115 3.8 Å
V161 3.6 Å
W165 3.5 Å
Y284 4.5 Å
I288 4.8 Å
D2 (NH) 2.3 Å
Backbone S285 3.4 Å
D Side chain K289 2.8 Å
R9 2.1 Å
Backbone Q111 3.0 Å
T1 2.3 Å
V Side chain W165 4.6 Å
F281 3.6 Å
Backbone H5 3.5 Å
D Side chain R9 3.2 Å
F10 (NH) 2.4 Å
Backbone R9 3.2 Å
H Side chain Y75 4.1 Å
H106 4.1 Å
P110 3.7 Å
H114 3.8 Å
V3 (CO) 3.5 Å
Backbone Y75 2.8 Å
V Side chain Y78 4.1 Å
T79 4.8 Å
H106 3.6 Å
Backbone Y83 3.8 Å
F Side chain Y22 4.3 Å
K23 3.7 Å
H26 3.9 Å
Y83 3.7 Å
A8 5.1 Å
Backbone S395 3.0 Å
A Side chain F7 5.1 Å
Backbone —
R Side chain Q372 4.1 Å
D399 4.0 Å
D2 2.1 Å
D4 3.2 Å, (CO) 3.9 Å
F10 (CO) 3.9 Å
Backbone N379 3.2 Å
Y391 2.8 Å
S395 3.3 Å
F Side chain Y391 3.5 Å
Backbone N379 3.3 Å
D4 2.4 Å
R9 3.9 Å
NH2 —
aResidues numbered 1–10 are in DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone
group was contacted. In the case in which a residue was contacted twice by the backbone of the same
ligand residue, O and H are used to distinguish the contacts.
doi:10.1371/journal.pone.0120492.t012
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Fig 13. RhpMS-Rmodel. The RhpMS-R backbone and the exposed atoms at the surface of the binding
pocket are highlighted; refer to Fig. 2 for notation, including sulfur represented as yellow. The pocket
contained a highly polar region near TM7 and hydrophobic and aromatic regions near TM5 and TM3.
Residues on TM1 were inaccessible for ligand interactions and the pocket was deepest between TM5 and
TM6.
doi:10.1371/journal.pone.0120492.g013
Fig 14. RhpMS-Rmolecular switches.RhpMS-R contained a unique ionic lock and novel 3–6 lock (shown)
similar to DrmMS-Rs. Receptor residues involved in the ionic lock (top left), 3–6 lock (top right), transmission
switch (bottom left), and tyrosine toggle switch (bottom right) are shown for RhpMS-R.
doi:10.1371/journal.pone.0120492.g014
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Fig 15. The 3–6 locks of domestic silkworm, honey bee, commonwater flea, red flour beetle, and termite MS-Rs. The 3–6 lock in (top: left to right)
BomMS-R, ApmMS-R1, ApmMS-R2, (bottom) DapMS-R, TrcMS-R, and ZonMS-R. The receptor residues on TM5 and TM6 that interacted with the 3–6 lock
are shown.
doi:10.1371/journal.pone.0120492.g015
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Fig 16. RhpMS docked to RhpMS-R. The ligand residues are pQ1(sand), D2 (olive), I3 (purple), D4 (cyan),
H5 (yellow), V6 (hot pink), F7 (orange), M8 (green), R9 (red), and F10 (blue). F7 and F10 made strong
hydrophobic contacts, D4 and R9 formed an ionic network near TM6, and the N terminus made general
interactions to TM3, TM4, and TM5.
doi:10.1371/journal.pone.0120492.g016
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Table 13. RhpMS contact sites on RhpMS-Ra.
pQ Side chain P164 4.9 Å
L165 3.9 Å
Backbone N209 3.3 Å
D Side chain — 4.3 Å
Backbone H5 3.1 Å
NH2 2.6 Å
I Side chain H114 5.0 Å
F210 4.4 Å
Y213 3.6 Å
Backbone Q111 2.4 Å
H5 3.5 Å
H5 (NH) 2.7 Å
NH2 2.8 Å
D Side chain H114 3.1 Å
R9 3.1 Å
Backbone Q111 3.0 Å
H114 O 3.2 Å, H 3.8 Å
H Side chain Q111 3.7 Å
D2 (NH) 3.1 Å
I3 (NH) 3.5 Å
V6 3.9 Å
F10 (CO) 2.7 Å
Backbone T110 3.3 Å
I3 (CO) 2.7 Å
V Side chain V103 4.0 Å
H106 3.7 Å
H5 3.9 Å
F7 4.0 Å
Backbone Y77 3.1 Å
F Side chain Y77 4.7 Å
V81 3.5 Å
M84 4.1 Å
Y85 4.3 Å
H106 3. Å
V6 4.0 Å
M84 5.1 Å
Backbone —
M Side chain G307 5.0 Å
F7 5.1 Å
Backbone R9 3.0 Å
R Side chain D311 3.3 Å
D4 3.1 Å
M84 (CO) 3.0 Å
Backbone NH2 3.2 Å
F Side chain V206 4.4 Å
F210 3.7 Å
I292 3.1 Å
Backbone H5 2.7 Å
NH2 D2 (CO) 2.6 Å
I3 (CO) 2.8 Å
R9 (CO) 3.2 Å
aResidues numbered 1–10 are in DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone
group was contacted. In the case in which a residue was contacted twice by the backbone of the same
ligand residue, O and H are used to distinguish the contacts.
doi:10.1371/journal.pone.0120492.t013
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Fig 17. [4–10]RhpMS docked to RhpMS-R. [4–10]RhpMS differed from RhpMS in ligand orientation, yet
contact sites were still retained through different ligand residues, consistent with its activity in heart.
doi:10.1371/journal.pone.0120492.g017
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Table 14. [4–10] RhpMS contact sites on RhpMS-Ra.
D Side chain N209 3.3 Å
D4 (NH) 2.2 Å
Backbone D2 2.2 Å
H5 3.2 Å
H Side chain Q111 3.7 Å
C162 5.0 Å
L165 4.4 Å
Y213 4.4 Å
D4 (NH) 3.2 Å
R9 3.3 Å
Backbone —
V Side chain F210 4.6 Å
Y213 3.7 Å
I217 4.4 Å
G285 5.0 Å
F7 3.8 Å
Backbone Q111 4.4 Å
F Side chain I118 4.1 Å
I217 4.9 Å
K218 4.1 Å
G285 3.6 Å
V6 3.8 Å
Backbone R9 (NH) 3.6 Å
M Side chain Q284 4.0 Å
L287 4.1 Å
G307 5.0 Å
M310 3.7 Å
A314 4.2 Å
R9 (NH) 3.4 Å
Backbone H114 4.1 Å
E281 3.8 Å
R Side chain S107 4.1 Å
Q111 3.7 Å
H5 3.3 Å
F10 (CO) 2.5 Å
Backbone F7 (CO) 3.6 Å
M8 3.4 Å
F Side chain Y77 3.6 Å
V81 3.8 Å
Y85 3.8 Å
H106 4.2 Å
Backbone R9 2.5 Å
NH2 —
aResidues numbered 1–10 are in DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone
group was contacted. In the case in which a residue was contacted twice by the backbone of the same
ligand residue, O and H are used to distinguish the contacts.
doi:10.1371/journal.pone.0120492.t014
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Fig 18. [5–10]RhpMS docked to RhpMS-R. Docking of [5–10]RhpMS was similar to that of RhpMS,
consistent SAR data that indicate the analog was active.
doi:10.1371/journal.pone.0120492.g018
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Together, the data from this study describe molecular switches involved in receptor activa-
tion and ligand contacts which provide insight into how the motifs are involved in MS signal-
ing. Additionally, a bioassay, and binding pockets, size and physicochemistry of the residues
available to make contacts supported published data demonstrating tissue-specificity of myo-
suppressin signaling and yielded information on MS SAR and its receptor in a disease vector.
Table 15. [5–10] RhpMS contact sites on RhpMS-Ra.
H Side chain G285 4.9 Å
D311 3.0 Å
A314 3.7 Å
M8 (NH) 2.7 Å, (CO) 3.3 Å
Backbone H114 3.4 Å
E281 3.7 Å
V Side chain F210 5.1 Å
Y213 4.1 Å
S214 4.4 Å
I217 4.2 Å
K218 3.8 Å
G285 4.4 Å
Backbone Q111 2.8 Å
F Side chain L161 5.1 Å
F210 4.9 Å
Y213 3.7 Å
R9 3.4 Å
Backbone R9 2.4 Å
M Side chain F210 3.9 Å
F7 4.3 Å
Backbone Q111 4.1 Å
H5 H 2.7 Å, O 3.3 Å
R Side chain F7 3.4 Å, (CO) 2.4 Å
Backbone Y77 3.3 Å
NH2 3.6 Å
F Side chain Y77 4.1 Å
V81 3.3 Å
M84 4.5 Å
Y85 4.0 Å
H106 4.1 Å
Backbone —
NH2 Y77 3.2 Å
Y85 4.1 Å
D311 2.6 Å
R9 (CO) 3.6 Å
aResidues numbered 1–10 are in DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone
group was contacted. In the case in which a residue was contacted twice by the backbone of the same
ligand residue, O and H are used to distinguish the contacts.
doi:10.1371/journal.pone.0120492.t015
Discovery of Novel Myosuppressin Signaling Switches
PLOS ONE | DOI:10.1371/journal.pone.0120492 March 20, 2015 33 / 40
Fig 19. [6–10]RhpMS docked to RhpMS-R. [6–10]RhpMS retained RhpMS contacts near TM5, but lacked
additional contacts of the parent peptide, consistent with its inactivity in heart.
doi:10.1371/journal.pone.0120492.g019
Table 16. [6–10] RhpMS contact sites on RhpMS-Ra.
V Side chain F7 3.9 Å
L165 4.8 Å
V206 4.2 Å
F210 3.5 Å
Backbone —
F Side chain V6 3.9 Å
L161 5.0 Å
L165 3.8 Å
Y213 3.9 Å
Backbone —
M Side chain Y213 4.3 Å
I217 3.6 Å
K218 3.7 Å
Backbone —
R Side chain D311 3.1 Å
Backbone —
F Side chain V206 3.4 Å
F210 3.6 Å
I292 3.7 Å
Backbone T291 2.4 Å
NH2 T291 3.0 Å
aResidues numbered 1–10 are in DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone
group was contacted. In the case in which a residue was contacted twice by the backbone of the same
ligand residue, O and H are used to distinguish the contacts.
doi:10.1371/journal.pone.0120492.t016
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Fig 20. RhpMS and DrmMS dose-response curves. RhpMS dose dependently decreased R. prolixus
cardiac contractility with an EC50* 140 nM. DrmMS dose dependently decreased prolixus cardiac
contractility with an EC50* 50 nM. The y-axis is the effect of RhpMS (top) and DrmMS (bottom) on heart
rate as percent of the saline response (100%). The x-axis is RhpMS or DrmMS concentration (molarity, M).
Mean values ± S.E.M were reported. N = 10 animals for each experimental condition.
doi:10.1371/journal.pone.0120492.g020
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Supporting Information
S1 Fig. [7–10]DrmMS docked to DrmMS-R1. [7–10]DrmMS retained few contacts of
DrmMS and the hydrophobic network between F7 and L8 was weakened in comparison to the
parent peptide, consistent with the inactivity of the analog.
(TIF)
S2 Fig. Y[Bpa2]DrmMS docked to DrmMS-R1. Y[Bpa2]DrmMS retained many of the
DrmMS contact sites with DrmMS-R1, thus, mimicking the parent peptide consistent with the
SAR data that established it is active in heart and gut. Y and Bpa2 are dark green and light
green, respectively.
(TIF)
S3 Fig. Y[Bpa4]DrmMS docked to DrmMS-R1. Y[Bpa4]DrmMS did not retain many of the
DrmMS contact sites with DrmMS-R1, thus, it did not mimic the parent peptide but was con-
sistent with the SAR data that established it as inactive in heart and gut. Bpa4 is dark red.
(TIF)
S4 Fig. [5–10]DrmMS docked to DrmMS-R2. [5–10]DrmMS retained many of the DrmMS
contact sites with DrmMS-R2, thus, it mimicked the parent peptide consistent with the SAR
data that established it was active in heart. It likely acts through DrmMS-R2.
(TIF)
S5 Fig. Y[Bpa2]DrmMS docked to DrmMS-R2. Y[Bpa2]DrmMS retained many of the
DrmMS contact sites with DrmMS-R1, thus, it mimicked the parent peptide consistent with
Table 17. RhpMS SAR data.
Heart Rate
Mean ± S.E.M. p value
RhpMS pQDIDHVFMRF-NH2 4 ± 3 0.0
[4–10]RhpMS DHVFMRF-NH2 49 ± 8 0.0
[5–10]RhpMS HVFMRF-NH2 50 ± 2 0.001
[6–10]RhpMS VFMRF-NH2 85 ± 11 0.7
DrmMS TDVDHVFLRF-NH2 7 ± 3 0.0
The effects of RhpMS, DrmMS, and N-terminally truncated RhpMS analogs are reported as Mean ± S.E.M.
at 1 μM calculated as percent of saline.
doi:10.1371/journal.pone.0120492.t017
Table 18. RhpMS and N-terminal truncation analog competition data.
Heart Rate
Mean ± S.E.M. p value
RhpMS + [4–10]RhpMS 49 ± 10 0.004
RhpMS + [5–10]RhpMS 62 ± 9 0.02
RhpMS + [6–10]RhpMS 38 ± 18 0.001
The effects of RhpMS and an N-terminal truncated RhpMS analog applied at equal concentrations (1 μM)
were reported as Mean ± S.E.M. calculated as percent of the saline response (100%).
doi:10.1371/journal.pone.0120492.t018
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the SAR data that established it was active in heart and gut.
(TIF)
S6 Fig. Y[Bpa4]DrmMS docked to DrmMS-R2. Y[Bpa4]DrmMS retained DrmMS interac-
tions, however, many of the interactions were made by different ligand residues and did not re-
tain the same physiochemical character, consistent with SAR data that established it had
diminished activity in heart and gut.
(TIF)
S7 Fig. [7–10]RhpMS docked to RhpMS-R. [7–10]RhpMS interacted with RhpMS contacts
near TM5 but failed to fill the pocket or retain additional RhpMS contacts, suggesting that [7–
10]RhpMS would not act through RhpMS-R.
(TIF)
S8 Fig. DrmMS docked to RhpMS-R. DrmMS docked to RhpMS-R with F7, L8, and F10
forming extensive hydrophobic interactions near TM5. D4, H5, and R9 generated an ionic net-
work that spanned from TM3 to TM7.
(TIF)
S9 Fig. [4–10]RhpMS, [5–10]RhpMS, and [6–10]RhpMS dose-response effects on R. pro-
lixus heart. The EC50 values were 32 nM, 31 nM, and 31 nM, respectively. The y-axis is the ef-
fect of [4–10]RhpMS (top), [5–10]RhpMS (middle), and [6–10]RhpMS (bottom) on heart rate
as percent of saline (100%). The x-axis is concentration as molarity, M. Mean values ± S.E.M
are reported.
(TIF)
S10 Fig. RhpMS and N-terminal truncated analogs on heart: competition curves. The EC50
values were 24 nM, 110 nM, and 54 nM, respectively. The y-axis is the effect of RhpMS + [4–
10]RhpMS (top), [5–10]RhpMS (middle), and [6–10]RhpMS (bottom) on heart rate as percent
of saline (100%). The x-axis is concentration as molarity, M. Mean values ± S.E.M are reported.
N = 10 animals for each experiment.
(TIF)
S1 Table. [7–10]DrmMS ligand-receptor contact sites on DrmMS-R1a. a Residues numbered
1–10 are in DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone group was
contacted. In the case in which a residue was contacted twice by the backbone or side chain of
the same ligand residue, O and H (backbone atoms), OH (hydroxyl of Y), and CO (carbonyl of
Bpa) are used to distinguish the contacts.
(DOCX)
S2 Table. Y[Bpa2]DrmMS contact sites on DrmMS-R1a. a Residues numbered 1–10 are in
DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone group was contacted.
In the case in which a residue was contacted twice by the backbone or side chain of the same li-
gand residue, O and H (backbone atoms), OH (hydroxyl of Y), and CO (carbonyl of Bpa) are
used to distinguish the contacts.
(DOCX)
S3 Table. Y[Bpa4]DrmMS contact sites on DrmMS-R1a. a Residues numbered 1–10 are in
DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone group was contacted.
In the case in which a residue was contacted twice by the backbone or side chain of the same li-
gand residue, O and H (backbone atoms), OH (hydroxyl of Y), and CO (carbonyl of Bpa) are
used to distinguish the contacts.
(DOCX)
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S4 Table. [5–10]DrmMS ligand-receptor contact sites on DrmMS-R2a. a Residues numbered
1–10 are in DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone group was
contacted. In the case in which a residue was contacted twice by the backbone or side chain of
the same ligand residue, O and H (backbone atoms), OH (hydroxyl of Y), and CO (carbonyl of
Bpa) are used to distinguish the contacts.
(DOCX)
S5 Table. Y[Bpa2]DrmMS contact sites on DrmMS-R2a. a Residues numbered 1–10 are in
DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone group was contacted.
In the case in which a residue was contacted twice by the backbone or side chain of the same li-
gand residue, O and H (backbone atoms), OH (hydroxyl of Y), and CO (carbonyl of Bpa) are
used to distinguish the contacts.
(DOCX)
S6 Table. Y[Bpa4]DrmMS contact sites on DrmMS-R2a. a Residues numbered 1–10 are in
DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone group was contacted.
In the case in which a residue was contacted twice by the backbone or side chain of the same li-
gand residue, O and H (backbone atoms), OH (hydroxyl of Y), and CO (carbonyl of Bpa) are
used to distinguish the contacts.
(DOCX)
S7 Table. [7–10]RhpMS ligand-receptor contact sites on RhpMS-Ra. a Residues numbered
1–10 are in DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone group was
contacted. In the case in which a residue was contacted twice by the backbone or side chain of
the same ligand residue, O and H (backbone atoms), OH (hydroxyl of Y), and CO (carbonyl of
Bpa) are used to distinguish the contacts.
(DOCX)
S8 Table. DrmMS ligand-receptor contact sites on RhpMS-Ra. a Residues numbered 1–10
are in DrmMS or RhpMS. (NH) and (CO) indicate that the residue backbone group was con-
tacted. In the case in which a residue was contacted twice by the backbone or side chain of the
same ligand residue, O and H (backbone atoms), OH (hydroxyl of Y), and CO (carbonyl of
Bpa) are used to distinguish the contacts.
(DOCX)
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